Keiser J, Utzinger J (April 2008). “Efficacy of current drugs against soil-transmitted helminth infections: systematic review and meta-analysis”. 《JAMA》 299 (16): 1937–48. doi:10.1001/jama.299.16.1937. PMID18430913.
Scheinfeld N, Rosenberg JD, Weinberg JM (2004). “Levamisole in dermatology : a review”. 《American Journal of Clinical Dermatology》 5 (2): 97–104. doi:10.2165/00128071-200405020-00004. PMID15109274.
Kouassi E, Caillé G, Léry L, Larivière L, Vézina M (1986). “Novel assay and pharmacokinetics of levamisole and p-hydroxylevamisole in human plasma and urine”. 《Biopharmaceutics & Drug Disposition》 7 (1): 71–89. doi:10.1002/bdd.2510070110. PMID3754161.
Luyckx M, Rousseau F, Cazin M, Brunet C, Cazin JC, Haguenoer JM, Devulder B, Lesieur I, Lesieur D, Gosselin P, Adenis L, Cappelaere P, Demaille A (1982). “Pharmacokinetics of levamisole in healthy subjects and cancer patients”. 《European Journal of Drug Metabolism and Pharmacokinetics》 7 (4): 247–54. doi:10.1007/bf03189626. PMID7166176.
Ho EN, Leung DK, Leung GN, Wan TS, Wong AS, Wong CH, Soma LR, Rudy JA, Uboh C, Sams R (April 2009). “Aminorex and rexamino as metabolites of levamisole in the horse”. 《Analytica Chimica Acta》 638 (1): 58–68. doi:10.1016/j.aca.2009.02.033. PMID19298880.
Hess C, Ritke N, Broecker S, Madea B, Musshoff F (May 2013). “Metabolism of levamisole and kinetics of levamisole and aminorex in urine by means of LC-QTOF-HRMS and LC-QqQ-MS”. 《Analytical and Bioanalytical Chemistry》 405 (12): 4077–88. doi:10.1007/s00216-013-6829-x. PMID23436169.
World Health Organization (2019). 《World Health Organization model list of essential medicines: 21st list 2019》. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
“Levamisole”. 《International Drug Price Indicator Guide》. 2018년 1월 22일에 원본 문서에서 보존된 문서. 2016년 12월 1일에 확인함.
nih.gov
ncbi.nlm.nih.gov
Keiser J, Utzinger J (April 2008). “Efficacy of current drugs against soil-transmitted helminth infections: systematic review and meta-analysis”. 《JAMA》 299 (16): 1937–48. doi:10.1001/jama.299.16.1937. PMID18430913.
Scheinfeld N, Rosenberg JD, Weinberg JM (2004). “Levamisole in dermatology : a review”. 《American Journal of Clinical Dermatology》 5 (2): 97–104. doi:10.2165/00128071-200405020-00004. PMID15109274.
Przegaliński E, Bigajska K, Siwanowicz J (1980). “Psychopharmacological profile of dexamisole”. 《Polish Journal of Pharmacology and Pharmacy》 32 (1): 21–9. PMID7454609.
Kouassi E, Caillé G, Léry L, Larivière L, Vézina M (1986). “Novel assay and pharmacokinetics of levamisole and p-hydroxylevamisole in human plasma and urine”. 《Biopharmaceutics & Drug Disposition》 7 (1): 71–89. doi:10.1002/bdd.2510070110. PMID3754161.
Luyckx M, Rousseau F, Cazin M, Brunet C, Cazin JC, Haguenoer JM, Devulder B, Lesieur I, Lesieur D, Gosselin P, Adenis L, Cappelaere P, Demaille A (1982). “Pharmacokinetics of levamisole in healthy subjects and cancer patients”. 《European Journal of Drug Metabolism and Pharmacokinetics》 7 (4): 247–54. doi:10.1007/bf03189626. PMID7166176.
Ho EN, Leung DK, Leung GN, Wan TS, Wong AS, Wong CH, Soma LR, Rudy JA, Uboh C, Sams R (April 2009). “Aminorex and rexamino as metabolites of levamisole in the horse”. 《Analytica Chimica Acta》 638 (1): 58–68. doi:10.1016/j.aca.2009.02.033. PMID19298880.
Hess C, Ritke N, Broecker S, Madea B, Musshoff F (May 2013). “Metabolism of levamisole and kinetics of levamisole and aminorex in urine by means of LC-QTOF-HRMS and LC-QqQ-MS”. 《Analytical and Bioanalytical Chemistry》 405 (12): 4077–88. doi:10.1007/s00216-013-6829-x. PMID23436169.
